{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-123002","form_type":"8-K","ticker":null,"cik":"0001745020","company_name":"Theseus Pharmaceuticals, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.291996+00:00","generated_at":"2026-06-07T18:48:44.367698+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Theseus Pharma terminates CEO and CMO; appoints CFO Dahms as President","bullets":["CEO Timothy Clackson and CMO David Kerstein terminated without cause effective Dec 7, 2023 as part of workforce reduction.","Clackson receives $0.9M severance plus 18-month equity vesting; Kerstein receives $0.6M plus 12-month equity vesting.","CFO Bradford Dahms appointed President and director; salary increased to $500K; eligible for retention bonus of 1.5x salary.","Dahms retention bonus paid in two installments; requires employment through earlier of strategic transaction or Feb 28, 2024.","Both departing executives entered consulting agreements through Mar 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-123002","json":"https://secwatch.observer/filing/0001104659-23-123002.json","markdown":"https://secwatch.observer/filing/0001104659-23-123002.md","text":"https://secwatch.observer/filing/0001104659-23-123002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745020/000110465923123002/0001104659-23-123002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745020/000110465923123002/tm2332045d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:48:44.367698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b540f668bd","claim":"Timothy P. Clackson was terminated as President and Chief Executive Officer at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"the Company terminated the employment of Timothy P. Clackson, Ph.D. as President and Chief Executive Officer of the Company, effective as of December 7, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465923123002/0001104659-23-123002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f399783baa","claim":"David Kerstein was terminated as Chief Medical Officer at Theseus Pharmaceuticals, Inc..","evidence_excerpt":"the Company also terminated the employment of David Kerstein, M.D. as the Chief Medical Officer of the Company, effective as of the Separation Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745020/000110465923123002/0001104659-23-123002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}